drugset / Trial / NCT03053362

THINC-it Vortioxetine - Sensitivity to Change

NCT03053362

Phase 2/3 Completed 158 enrolled Brain and Cognition Discovery Foundation
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the sensitivity of the THINC-it tool, in measuring change in cognitive deficits in individuals with MDD after receiving vortioxetine.

Timeline

Start
2017-05-24
Primary completion
2018-08-08
Completion
2018-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg
Subject Vortioxetine Unknown 20 mg